Clinical Trials · NCT00935532
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 427
- Start date
- Jul 2009
- Locations
- 22 sites, Japan
- Primary endpoint
- Change in HbA1c From Baseline to Endpoint (Week 26)